Bonum Therapeutics
Kendyl Daniels is a Scientist I at Bonum Therapeutics since September 2022, previously serving as a Sr. Associate Scientist at Good Therapeutics, Inc. from March 2021 to September 2022. Prior experience includes a role as Research Scientist II at Seattle Children's from January 2017 to March 2021, focusing on in-process and release testing for CAR-T cell therapy, utilizing techniques such as flow cytometry and qPCR. Earlier experience involves working as a Lab Assistant III in the same therapeutic core, ensuring lab efficiency and maintenance of human stem cell lines within GMP facilities. Kendyl holds a Bachelor of Science degree in Mathematics and Biology from Western Washington University, earned between 2013 and 2016.
Bonum Therapeutics
Bonum Therapeutics is creating a technology platform that can be used to treat a wide range of diseases, including cancer which is the company’s primary therapeutic area of focus—as well as metabolic diseases, immunology, and pain management.